Comparing screening mammography for early breast cancer detection in Vermont and Norway
- PMID: 18664650
- PMCID: PMC2720695
- DOI: 10.1093/jnci/djn224
Comparing screening mammography for early breast cancer detection in Vermont and Norway
Abstract
Background: Most screening mammography in the United States differs from that in countries with formal screening programs by having a shorter screening interval and interpretation by a single reader vs independent double reading. We examined how these differences affect early detection of breast cancer by comparing performance measures and histopathologic outcomes in women undergoing opportunistic screening in Vermont and organized screening in Norway.
Methods: We evaluated recall, screen detection, and interval cancer rates and prognostic tumor characteristics for women aged 50-69 years who underwent screening mammography in Vermont (n = 45 050) and in Norway (n = 194 430) from 1997 through 2003. Rates were directly adjusted for age by weighting the rates within 5-year age intervals to reflect the age distribution in the combined data and were compared using two-sided Z tests.
Results: The age-adjusted recall rate was 9.8% in Vermont and 2.7% in Norway (P < .001). The age-adjusted screen detection rate per 1000 woman-years after 2 years of follow-up was 2.77 in Vermont and 2.57 in Norway (P = .12), whereas the interval cancer rate per 1000 woman-years was 1.24 and 0.86, respectively (P < .001). Larger proportions of invasive interval cancers in Vermont than in Norway were 15 mm or smaller (55.9% vs 38.2%, P < .001) and had no lymph node involvement (67.5% vs 57%, P = .01). The prognostic characteristics of all invasive cancers (screen-detected and interval cancer) were similar in Vermont and Norway.
Conclusion: Screening mammography detected cancer at about the same rate and at the same prognostic stage in Norway and Vermont, with a statistically significantly lower recall rate in Norway. The interval cancer rate was higher in Vermont than in Norway, but tumors that were diagnosed in the Vermont women tended to be at an earlier stage than those diagnosed in the Norwegian women.
Figures
Similar articles
-
Changes in breast cancer risk distribution among Vermont women using screening mammography.J Natl Cancer Inst. 2014 Jun 23;106(8):dju157. doi: 10.1093/jnci/dju157. Print 2014 Aug. J Natl Cancer Inst. 2014. PMID: 24957223 Free PMC article.
-
Sensitivity and specificity of mammographic screening as practised in Vermont and Norway.Br J Radiol. 2012 Dec;85(1020):e1226-32. doi: 10.1259/bjr/15168178. Epub 2012 Sep 19. Br J Radiol. 2012. PMID: 22993383 Free PMC article.
-
Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study.Lancet Oncol. 2016 Aug;17(8):1105-1113. doi: 10.1016/S1470-2045(16)30101-2. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345635
-
Digital Breast Tomosynthesis with Hologic 3D Mammography Selenia Dimensions System for Use in Breast Cancer Screening: A Single Technology Assessment [Internet].Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08. Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2017 Sep 4. Report from the Norwegian Institute of Public Health No. 2017-08. PMID: 29553669 Free Books & Documents. Review.
-
Breast cancer screening in developing countries.Clinics (Sao Paulo). 2017 Apr;72(4):244-253. doi: 10.6061/clinics/2017(04)09. Clinics (Sao Paulo). 2017. PMID: 28492725 Free PMC article. Review.
Cited by
-
COVID-19 related change in breast cancer diagnosis, stage, treatment, and case volume: 2019-2021.Breast Cancer Res Treat. 2023 Nov;202(1):105-115. doi: 10.1007/s10549-023-06962-8. Epub 2023 Aug 16. Breast Cancer Res Treat. 2023. PMID: 37584882 Free PMC article.
-
Interpreting Breast Cancer Mortality Trends Related to Introduction of Mammography Screening: A Simulation Study.MDM Policy Pract. 2022 Oct 8;7(2):23814683221131321. doi: 10.1177/23814683221131321. eCollection 2022 Jul-Dec. MDM Policy Pract. 2022. PMID: 36225967 Free PMC article.
-
Comparison of the ductal carcinoma in situ between White Americans and Chinese Americans.Medicine (Baltimore). 2021 Jan 22;100(3):e24136. doi: 10.1097/MD.0000000000024136. Medicine (Baltimore). 2021. PMID: 33546026 Free PMC article.
-
Breast cancer distant recurrence lead time interval by detection method in an institutional cohort.BMC Cancer. 2020 Nov 20;20(1):1124. doi: 10.1186/s12885-020-07609-3. BMC Cancer. 2020. PMID: 33218313 Free PMC article.
-
The potential of breast cancer screening in Europe.Int J Cancer. 2021 Jan 15;148(2):406-418. doi: 10.1002/ijc.33204. Epub 2020 Jul 30. Int J Cancer. 2021. PMID: 32683673 Free PMC article.
References
-
- Houn F, Brown ML. Current practice of screening mammography in the United States: data from the National Survey of Mammography Facilities. Radiology. 1994;190(1):209–215. - PubMed
-
- US Preventive Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med. 2002;137(5 pt 1):344–346. - PubMed
-
- Hofvind S, Geller B, Vacek P, Thoresen S, Skaane P. Using the European Guidelines to evaluate the Norwegian Breast Cancer Screening Program. Eur J Epidemiol. 2007;22(7):447–455. - PubMed
-
- Perry N, Broeders M, deWolf C, Törnberg S, Holland R, von Karsa L. European Guidelines for Quality Assurance in Breast Cancer Screening and Diagnosis. [Printed in Belgium]. European Communities: 2006. http://bookshop.eu.int ISBN: 92-79-01258-4. Accessed January 15, 2008. - PubMed
-
- Ballard-Barbash R, Klabunde C, Paci E, et al. Breast cancer screening in 21 countries: delivery of services, notification of results and outcomes ascertainment. Eur J Cancer Prev. 1999;8(5):417–426. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
